ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Allergan (AGN)
06/23/201608:00:00Allergan Announces FDA Approval of Supplemental New Drug Application...
06/21/201609:30:00Teva and Allergan Sell Generic Drugs to Impax In Latest Divestiture
06/21/201609:17:00Teva and Allergan Sell Generic Drugs to Impax In Latest Divestiture
06/20/201608:01:00Data Presented at ASM Microbe Highlight In Vitro Antimicrobial...
06/17/201614:30:00Former Warner Chilcott Executive Acquitted of Kickbacks Charge
06/17/201608:00:00Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon...
06/16/201611:07:00Teva, Looking to Close Actavis Deal, Sells $40 Million Portfolio...
06/15/201607:31:00Allergan Announces FDA Acceptance of the 510(k) Premarket Notification...
06/14/201620:11:00Lilly: German Supreme Court Grants Appeal in Dispute With Actavis
06/14/201608:31:00Allergan Reaches Out To Family Caregivers Of People With Alzheimer's...
06/13/201608:31:00Allergan to Present New Data from its Anti-Infectives Portfolio...
06/11/201613:58:00Dr. Reddy's Buying Eight Drugs From Teva for U.S. Market
06/10/201608:31:00Study Reveals Gender Differences in Migraine Treatment
06/09/201608:31:00ActuallySheCan(SM) By Allergan Launches Limited Edition #ActuallySheCan(SM...
06/09/201608:01:00Ironwood and Allergan Announce Supplemental New Drug Application...
06/08/201619:01:54Statement of Changes in Beneficial Ownership (4)
06/08/201618:58:31Statement of Changes in Beneficial Ownership (4)
06/08/201618:00:00AmSurg, Envision Healthcare Hold Merger Talks
06/08/201607:30:00The Allergan Foundation And The Jed Foundation Announce Three-Year...
06/06/201617:33:56Statement of Changes in Beneficial Ownership (4)

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations